Cibc Asset Management Inc Blueprint Medicines Corp Transaction History

Cibc Asset Management Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 06, 2022	SELL	$54.1 - $110.08 $137,197 - $279,162	-2,536 Closed	0 $0
Q4 2021 Feb 08, 2022	BUY	$94.25 - $115.99 $15,834 - $19,486	168 Added 7.09%	2,536 $272,000
Q3 2021 Nov 09, 2021	BUY	$80.98 - $109.47 $191,760 - $259,224	2,368 New	2,368 $243,000
Q2 2021 Aug 16, 2021	SELL	$82.78 - $101.0 $171,768 - $209,575	-2,075 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$90.71 - $108.28 $13,697 - $16,350	151 Added 7.85%	2,075 $202,000
Q4 2020 Feb 03, 2021	BUY	$92.08 - $124.48 $177,161 - $239,499	1,924 New	1,924 $216,000

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.47B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Cibc Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Cibc Asset Management Inc with notifications on news.